Wells Fargo’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1,125
| Closed | -$2K | – | 7926 |
|
|
2022
Q2 | $2K | Sell |
1,125
-489
| -30% | -$976 | ﹤0.01% | 6442 |
|
|
2022
Q1 | $3K | Hold |
1,614
| – | – | ﹤0.01% | 6637 |
|
|
2021
Q4 | $3K | Buy |
1,614
+1
| +0.1% | +$3 | ﹤0.01% | 6853 |
|
|
2021
Q3 | $5K | Buy |
1,613
+39
| +2% | +$106 | ﹤0.01% | 6404 |
|
|
2021
Q2 | $4K | Sell |
1,574
-1,997
| -56% | -$4.51K | ﹤0.01% | 6432 |
|
|
2021
Q1 | $7K | Buy |
3,571
+2
| +0.1% | +$6 | ﹤0.01% | 6435 |
|
|
2020
Q4 | $9K | Sell |
3,569
-2,000
| -36% | -$3.93K | ﹤0.01% | 6050 |
|
|
2020
Q3 | $11K | Buy |
5,569
+53
| +1% | +$151 | ﹤0.01% | 5883 |
|
|
2020
Q2 | $16K | Sell |
5,516
-2,500
| -31% | -$6.83K | ﹤0.01% | 5755 |
|
|
2020
Q1 | $21K | Sell |
8,016
-1,484
| -16% | -$6.68K | ﹤0.01% | 5595 |
|
|
2019
Q4 | $47K | Buy |
9,500
+500
| +6% | +$2.71K | ﹤0.01% | 5535 |
|
|
2019
Q3 | $54K | Buy |
9,000
+2,000
| +29% | +$13.4K | ﹤0.01% | 5542 |
|
|
2019
Q2 | $45K | Buy |
7,000
+500
| +8% | +$3.21K | ﹤0.01% | 5587 |
|
|
2019
Q1 | $44K | Buy |
6,500
+500
| +8% | +$3K | ﹤0.01% | 5354 |
|
|
2018
Q4 | $24K | Buy |
+6,000
| New | +$39.5K | ﹤0.01% | 5734 |
|
Wells Fargo's ETTX Position: Q3 2022 in Review
Wells Fargo sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q3 2022, closing a stake of 1,125 shares — an estimated $2K sold.
Wells Fargo first reported a position in ETTX in Q4 2018 and held it in 15 quarters. The position peaked at $54K in Q3 2019. 0 funds tracked by Wall St. Rank hold ETTX as of Q3 2022.
- Wells Fargo reported no remaining Entasis Therapeutics Holdings Inc. position as of Q3 2022 after selling out during the quarter.
- Wells Fargo sold 1,125 Entasis Therapeutics Holdings Inc. shares in Q3 2022, an estimated $2K.
- Wells Fargo first reported a position in Entasis Therapeutics Holdings Inc. in Q4 2018 and held it in 15 quarters.
- Wells Fargo's Entasis Therapeutics Holdings Inc. position peaked at $54K in Q3 2019.
- 0 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q3 2022.
Based on Wells Fargo's 13F filing for Q3 2022, filed 14 Nov 2022.